ORMP ORAMED PHARMACEUTICALS INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1176309 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY435.3%
TTM EPS YoY412.5%
Revenue 3-yr CAGR-11.9%
Net income 3-yr CAGR—
Margins
Gross margin0.7%
Operating margin-754.4%
Net margin3,202.5%
FCF margin-457.7%
EBITDA margin-748.4%
Returns
ROE37.0%
ROA33.2%
ROIC (approx.)-10.4%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets13.5%
Debt / equity0.00x
Current ratio6.98x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.14x
Accruals ratio37.9%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | $2.00M | — |
| Cost of revenue | — | — | — | $0 | $0 | $0 | $1.99M | — |
| Gross profit | — | — | — | $0 | $0 | $0 | $13,000 | — |
| R&D expense | $0 | $0 | $1.59M | $1.99M | $1.15M | $1.03M | $2.21M | $1.46M |
| SG&A expense | $4.10M | $2.77M | $2.06M | $3.68M | $1.27M | $1.46M | $2.31M | $2.13M |
| Operating income | -$4.10M | -$2.77M | -$3.66M | -$5.67M | -$2.43M | -$2.49M | -$4.50M | -$3.60M |
| Interest expense | — | — | — | — | — | — | — | $0 |
| Pretax income | $28.28M | $101.59M | $49.44M | $9.80M | $59.45M | $13.13M | -$7.06M | -$9.78M |
| Income tax | $9.87M | $23.43M | $11.13M | -$212,000 | $11.06M | -$126,000 | $584,000 | $416,000 |
| Net income | $18.41M | $78.16M | $38.31M | $10.01M | $48.40M | $13.29M | -$7.64M | -$10.23M |
| EBITDA | -$4.07M | -$2.73M | -$3.63M | -$5.64M | -$2.40M | -$2.46M | -$4.47M | -$3.56M |
| EPS (basic) | 0.44 | 1.90 | 0.94 | — | 1.16 | 0.32 | -0.19 | — |
| EPS (diluted) | 0.43 | 1.84 | 0.91 | — | 1.13 | 0.31 | -0.19 | — |
| Weighted avg. shares (diluted) | 43.02M | 42.50M | 41.97M | — | 42.77M | 42.61M | 41.23M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $28.93M | $15.24M | $13.20M | $45.95M | $52.18M | $15.80M | $74.52M | $54.42M |
| Short-term investments | $583,000 | $846,000 | $4.96M | $5.42M | $4.96M | $1.75M | $3.69M | $3.44M |
| Current assets | $57.38M | $53.41M | $68.15M | $133.27M | $136.12M | $99.03M | $131.48M | $143.22M |
| PP&E, net | $506,000 | $532,000 | $561,000 | $586,000 | $614,000 | $645,000 | $671,000 | $698,000 |
| Total assets | $400.92M | $369.64M | $268.85M | $230.86M | $220.49M | $161.68M | $147.54M | $155.28M |
| Current liabilities | $9.45M | $10.73M | $10.56M | $19.09M | $6.12M | $3.69M | $5.49M | $5.68M |
| Total liabilities | $61.83M | $52.17M | $30.57M | $31.12M | $18.16M | $8.10M | $7.64M | $9.93M |
| Shareholders' equity | $339.09M | $317.47M | $238.28M | $199.74M | $203.28M | $154.53M | $140.81M | $146.26M |
| Shares outstanding | 43.24M | 41.31M | 40.93M | 39.28M | 40.84M | 40.85M | 40.85M | 39.92M |
| Cash flow statement | ||||||||
| Operating cash flow | $426,000 | -$200,000 | -$2.92M | -$466,000 | -$1.62M | -$3.54M | -$3.52M | -$1.91M |
| Capital expenditure | $4,000 | $2,000 | $5,000 | $2,000 | $0 | $4,000 | $3,000 | $11,000 |
| Free cash flow | $422,000 | -$202,000 | -$2.92M | -$468,000 | -$1.62M | -$3.54M | -$3.52M | -$1.92M |
| Investing cash flow | $13.19M | $4.31M | -$19.49M | -$1.68M | $38.36M | -$54.85M | $23.62M | $15.42M |
| Financing cash flow | $40,000 | -$1.95M | -$10.36M | -$4.01M | -$361,000 | — | — | -$1.20M |
| Depreciation & amortization | $30,000 | $31,000 | $30,000 | $30,000 | $31,000 | $30,000 | $30,000 | $31,000 |
| Stock-based compensation | $3.11M | $1.39M | $1.74M | $2.28M | $719,000 | $800,000 | $2.19M | $1.23M |
| Dividends paid | $57,000 | $78,000 | $10.36M | — | — | — | — | — |
| Share buybacks | — | — | — | $4.01M | $361,000 | — | — | $1.19M |
Free plan shows the latest 8 periods; Pro shows all 69 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.